Synthorx Inc (NASDAQ:THOR) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Synthorx in a report issued on Wednesday, March 13th. Jefferies Financial Group analyst B. Amin anticipates that the medical instruments supplier will post earnings per share of ($0.33) for the quarter. Jefferies Financial Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Financial Group also issued estimates for Synthorx’s Q2 2019 earnings at ($0.39) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($1.52) EPS, FY2020 earnings at ($2.94) EPS, FY2021 earnings at ($2.99) EPS, FY2022 earnings at ($2.98) EPS and FY2023 earnings at ($3.53) EPS.
Synthorx (NASDAQ:THOR) last announced its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.77).
Other analysts have also issued reports about the company. HC Wainwright started coverage on Synthorx in a report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price objective for the company. Leerink Swann initiated coverage on Synthorx in a report on Friday. They set an “outperform” rating for the company.
Shares of NASDAQ:THOR opened at $19.21 on Friday. Synthorx has a 1 year low of $11.00 and a 1 year high of $23.53. The firm has a market cap of $488.90 million and a P/E ratio of -2.92.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC bought a new position in Synthorx during the fourth quarter valued at about $38,559,000. RA Capital Management LLC bought a new position in Synthorx during the fourth quarter valued at about $169,014,000. Orbimed Advisors LLC bought a new position in Synthorx during the fourth quarter valued at about $92,398,000. Monashee Investment Management LLC bought a new position in Synthorx during the fourth quarter valued at about $435,000. Finally, Dean Capital Investments Management LLC bought a new position in Synthorx during the fourth quarter valued at about $827,000. Institutional investors own 75.85% of the company’s stock.
Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.
Recommended Story: Trading Strategy
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.